ImmunoForge

About ImmunoForge

ImmunoForge, a South Korean biopharmaceutical company established in 2017, is focused on the development of novel therapeutics for rare and intractable diseases. The company was co-founded by Sung-min Ahn, a translational scientist with a background in cancer genomics from Gachon University Gil Medical Center, and Kiho Chang, who brings over 25 years of experience in new drug development and global business from tenures at major pharmaceutical firms like Dong-A and LG Life Sciences. Their combined expertise in medical science and the biopharmaceutical business process underpins the company's strategy.

The company's core business revolves around its proprietary Elastin-Like Polypeptide (ELP) platform technology, which is designed to significantly extend the half-life of peptide and protein drugs, potentially by up to 200 times. This technology addresses a critical challenge in drug delivery, aiming to create more effective and tolerable long-term treatments. ImmunoForge's business model centers on advancing its pipeline candidates through preclinical and clinical trials, with a strategy that includes securing partnerships and licensing agreements for commercialization. An expanded licensing agreement with Duke University, where the ELP technology originated, exemplifies this approach, granting ImmunoForge rights for all therapeutic areas except anticancer drugs, for which Duke retains development rights with a profit-sharing arrangement.

ImmunoForge's product pipeline targets conditions with high unmet medical needs, including rare musculoskeletal disorders, cancer, and metabolic diseases. A lead candidate, Froniglutide (PF1801), is a long-acting biologic currently in Phase 2 clinical trials for treating idiopathic inflammatory myopathies like polymyositis and dermatomyositis. Another key asset is Pemziviptadil (PF1804), a treatment for cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD), which has received IND approval for a Phase 2 trial from the U.S. FDA. The company has successfully garnered multiple Orphan Drug Designations (ODD) from the FDA for its candidates, which provides benefits such as market exclusivity and tax credits on clinical trials.